Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2009. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by eight individuals on March 10, 2009, at a price of £9.95 per share through the Company's Share Reward Plan. The transactions involved both personal contributions (partnership element) and company contributions (matching element). Specific acquisitions included:
- Mr A P Witty: 13 shares (personal) and 13 shares (company match).
- Mr J S Heslop: 13 shares (personal) and 13 shares (company match).
- Mr S M Bicknell: 13 shares (personal) and 13 shares (company match).
- Mr E J Gray: 13 shares (personal) and 13 shares (company match).
- Mr S A Hussain: 12 shares (personal) and 12 shares (company match).
- Mr D Learmouth: 13 shares (personal) and 13 shares (company match).
- Mr D S Redfern: 13 shares (personal) and 13 shares (company match).
- Ms C Thomas: 13 shares (personal) and 13 shares (company match).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of £9.95 per Ordinary share on March 10, 2009.
- Confirm the total number of shares acquired by each listed director under the Share Reward Plan.
- Review the company's broader financial reports (e.g., Form 20-F) for actual financial performance metrics, as this filing contains none.